A commentary notes that although encouraging, mature overall survival data are needed before making any decision for regulatory approval of utidelone. It acknowledges that new treatments such as utidelone, with new mechanisms of action and non-overlapping toxicity profiles are needed, particularly for patients with refractory disease.